Systemic Lupus Erythematosus News and Research

RSS
Systemic lupus erythematosus (SLE) is the form of the disease that most people are referring to when they say "lupus." The word "systemic" means the disease can affect many parts of the body. The symptoms of SLE may be mild or serious. Although SLE usually first affects people between the ages of 15 and 45 years, it can occur in childhood or later in life as well.
Anthera initiates PEARL-SC Phase 2b study of A-623 for lupus

Anthera initiates PEARL-SC Phase 2b study of A-623 for lupus

30 Jul 2010
Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

28 Jul 2010
Susceptibility to Behcet's disease associated with genes involved in body's immune response

Susceptibility to Behcet's disease associated with genes involved in body's immune response

14 Jul 2010
TLR7, TLR9 proteins could be culprit behind lupus patients' resistance to steroid treatments: Scientists

TLR7, TLR9 proteins could be culprit behind lupus patients' resistance to steroid treatments: Scientists

13 Jul 2010
Human Genome Sciences, Lonza announce commercial supply agreement for BENLYSTA

Human Genome Sciences, Lonza announce commercial supply agreement for BENLYSTA

13 Jul 2010
Compugen's CGEN-15001 recombinant fusion protein abolishes spontaneous relapses in animal model of MS

Compugen's CGEN-15001 recombinant fusion protein abolishes spontaneous relapses in animal model of MS

2 Jul 2010
PIKAMAB secures exclusive rights to issued U.S. patent from UABRF

PIKAMAB secures exclusive rights to issued U.S. patent from UABRF

1 Jul 2010
Additional results from BLISS-76 Phase 3 trial of BENLYSTA presented at International Congress on SLE

Additional results from BLISS-76 Phase 3 trial of BENLYSTA presented at International Congress on SLE

28 Jun 2010
Anthera commences enrollment in pivotal VISTA-16 Phase 3 clinical study of varespladib

Anthera commences enrollment in pivotal VISTA-16 Phase 3 clinical study of varespladib

23 Jun 2010
Corgenix receives new European patent for AtherOx technology

Corgenix receives new European patent for AtherOx technology

23 Jun 2010
Phase IIb EMBLEM study results of epratuzumab in patients with SLE presented at EULAR 2010

Phase IIb EMBLEM study results of epratuzumab in patients with SLE presented at EULAR 2010

21 Jun 2010
SLE and RA negatively affect patients' emotional relationships, sex lives: Study

SLE and RA negatively affect patients' emotional relationships, sex lives: Study

18 Jun 2010
Additional results from BLISS-52 Phase 3 trial of BENLYSTA for SLE to be presented at EULAR 2010

Additional results from BLISS-52 Phase 3 trial of BENLYSTA for SLE to be presented at EULAR 2010

18 Jun 2010
Interim epidemiological information on SLE patients in China presented at EULAR 2010

Interim epidemiological information on SLE patients in China presented at EULAR 2010

18 Jun 2010
Effects of SLE may differ based on patient's genealogical heritage: Study

Effects of SLE may differ based on patient's genealogical heritage: Study

18 Jun 2010
HGS, GSK announce full presentation of BLISS-76 Phase 3 BENLYSTA trial results for SLE at EULAR 2010

HGS, GSK announce full presentation of BLISS-76 Phase 3 BENLYSTA trial results for SLE at EULAR 2010

17 Jun 2010
Phase IIb EMBLEM study demonstrates clinical efficacy of epratuzumab in patients with SLE

Phase IIb EMBLEM study demonstrates clinical efficacy of epratuzumab in patients with SLE

16 Jun 2010
Report on treatment trends in systemic lupus erythematosus

Report on treatment trends in systemic lupus erythematosus

16 Jun 2010
Human Genome Sciences submits BLA for BENLYSTA to FDA

Human Genome Sciences submits BLA for BENLYSTA to FDA

10 Jun 2010
UC-MSCT improves symptoms, biochemical values in patients with severe refractory SLE: Study

UC-MSCT improves symptoms, biochemical values in patients with severe refractory SLE: Study

8 Jun 2010

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback